Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead

Showing 15 posts of 239 posts found.

shutter

Japan approves Gilead and Eisai’s Jyseleca for rheumatoid arthritis

September 25, 2020
Medical Communications, Sales and Marketing Eisai, Gilead, Japan, Jyseleca

Gilead and Eisai have secured approval for their oral JAK1 preferential inhibitor Jyseleca (filgotinib) from the Japanese Ministry of Health, …

News
49449461223_6e279556d2_b

Gilead agrees to pay $97 million to settle Medicare kickbacks case

September 24, 2020
Business Services Gilead, Medicare, drugs, kickbacks

Gilead has agreed to pay $97 million to resolve claims from the US Government that it used an independent charity …

News
shutterstock_273326141

Gilead scoops up Immunomedics in deal worth $21 billion

September 14, 2020
Sales and Marketing Gilead, Immunomedics, acquisition, pharma

The Board of Directors from both companies have unanimously agreed for Gilead to acquire Immunomedics for $88 per share in …

News
shutterstock_138095450

Gilead and Jounce Therapeutics forge immuno-oncology partnership worth a potential $700m+

September 2, 2020
Research and Development, Sales and Marketing Gilead, jounce, oncology, pharma

Gilead and Jounce Therapeutics have come together in a new immuno-oncology partnership potentially worth over $700 million. The primary drive …

News
remsss

Gilead says FDA could expand eligibility of coronavirus patients for remdesivir

August 24, 2020
Sales and Marketing FDA, Gilead

The FDA could expand its Emergency Use Authorization (EUA) for Gilead’s remdesivir for treating coronavirus patients, according to Gilead.

News
gilead-sciences

FDA turns down Gilead’s JAK inhibitor filgotinib in rheumatoid arthritis, endangering 2020 approval hopes

August 20, 2020
Research and Development, Sales and Marketing FDA, Gilead, filgotinib

Gilead’s JAK inhibitor filgotinib has been unexpectedly knocked back by the FDA as a therapy to treat moderately to severely …

News
shutterstock_158366573

Racial minority groups are not adequately represented in COVID-19 clinical studies, research argues

August 12, 2020
Research and Development COVID-19, Gilead, pharma, remdesivir

New research has warned that minority groups and people of colour are underrepresented in current trials for COVID-19 therapies, despite …

News
fda

Gilead applies for FDA approval to treat coronavirus patients with remdesivir

August 11, 2020
Manufacturing and Production COVID-19, Gilead, coronavirus

Gilead Sciences has asked the FDA to approve its drug remdesivir to treat COVID-19 patients. The drug would go under …

News
fdaoutsideweb

Kite secures FDA approval for second CAR T therapy Tecartus in relapsed or refractory mantle cell lymphoma

July 27, 2020
Sales and Marketing CAR T, CAR-T, FDA, Gilead, kite pharma

Kite Pharma has chalked up another regulatory success for its parent company Gilead with the news that the FDA has …

News
mylan_building

Mylan launches generic version of Gilead’s remdesivir for COVID-19 patients in India

July 20, 2020
Sales and Marketing COVID-19, Gilead, India, Mylan, generic, remdesivir

Mylan has launched its own generic version of Gilead’s remdesivir on the Indian market for the treatment of patients with …

News
shutterstock_159488225

New data shows Gilead’s remdesivir “potently inhibited” SARS-CoV-2 in human lung cell cultures

July 10, 2020
Medical Communications, Research and Development COVID-19, Gilead, coronavirus, remdesivir

New findings published from researchers at Vanderbilt University Medical Center (VUMC) at the University of North Carolina, as well as …

News
shutterstock_273326141

Gilead acquires 49.9% of Pionyer Therapeutics in potential $1.5bn+ deal

June 24, 2020
Research and Development, Sales and Marketing Gilead, Pionyr, pharma

Gilead has announced its intention to acquire 49.9% of shares in cancer immunotherapy specialist Pionyr Therapeutics with a payment of …

News
gilead-sciences

Gilead to investigate inhaled formulation of promising COVID-19 therapy remdesivir

June 23, 2020
Manufacturing and Production, Research and Development COVID-19, Gilead, remdesivir

Gilead is intent on pushing the applications of its antiviral drug remdesivir after it has shown efficacy in the treatment …

News
remdesivir_ulrich_perrey

EMA could approve Gilead’s streamlined remdesivir application for COVID-19 “within weeks”

June 9, 2020
Manufacturing and Production, Sales and Marketing COVID-19, EU, Gilead, coronavirus, remdesivir

The European Medicines Agency has received the application from Gilead for the first conditional marketing authorisation (CMA) of its antiviral …

News
remdesivir_ulrich_perrey

Australian Taskforce recommends Gilead’s remdesivir for routine use in the country’s COVID-19 patients

June 5, 2020
Medical Communications, Sales and Marketing Australia, COVID-19, Gilead, coronavirus, remdesivir

Australia could be set to follow the decisions of other nations around the world in officially licensing Gilead’s antiviral therapy …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024